| First Author | Adam A | Year | 2023 |
| Journal | NPJ Vaccines | Volume | 8 |
| Issue | 1 | Pages | 160 |
| PubMed ID | 37863935 | Mgi Jnum | J:358202 |
| Mgi Id | MGI:7778592 | Doi | 10.1038/s41541-023-00753-4 |
| Citation | Adam A, et al. (2023) A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity. NPJ Vaccines 8(1):160 |
| abstractText | An attenuated SARS-CoV-2 virus with modified viral transcriptional regulatory sequences and deletion of open-reading frames 3, 6, 7 and 8 (3678) was previously reported to protect hamsters from SARS-CoV-2 infection and transmission. Here we report that a single-dose intranasal vaccination of 3678 protects K18-hACE2 mice from wild-type or variant SARS-CoV-2 challenge. Compared with wild-type virus infection, the 3678 vaccination induces equivalent or higher levels of lung and systemic T cell, B cell, IgA, and IgG responses. The results suggest 3678 as an attractive mucosal vaccine candidate to boost pulmonary immunity against SARS-CoV-2. |
